A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecle ...
Stem Cell Transplant Complications;EBV+ Sarcomas;Leiomyosarcoma;Epstein-Barr Virus (EBV)-Associated Diseases;EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD);EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD);EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD);EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD);Solid Organ Transplant Complications;Lymphoproliferative Disorders;Allogeneic Hematopoietic Cell Transplant;Chronic Active Epstein-Barr Virus (CAEBV);Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH);Lymphohistiocytosis, Hemophagocytic Stem Cell Transplant Complications;EBV+ Sarcomas;Leiomyosarcoma;Epstein-Barr Virus (EBV)-Associated ...
Biological: Tabelecleucel
Atara Biotherapeutics
NULL
Recruiting
N/A
N/A
All
228
Phase 2
United States;Austria;Belgium;France;Italy;Spain;United Kingdom
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies Expanded Access Protocol for Tabelecleucelfor Patients With Epstein-Barr Virus-Associated Viremia or ...
Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies Expanded Access Protocol for Providing Tabelecleucelto Patients With Epstein-Barr Virus-Associated V ...